Pricing for Oncology Biosimilars | ClinicLens
To the Editor We wish to express several concerns regarding the article on hospital adoption and pricing for oncology biosimilars. First, we disagree with the statement that “Medicare bases its reimbursement for biosimilars on the high acquisition price for the biologic, not the
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.